中西医结合治疗免疫性狼疮鼠的实验研究
|
摘要
第一部分SLE小鼠模型的建立
目的:探讨腹腔注射细菌脂多糖(LPS)制造SLE小鼠模型的最佳剂量。方法:80只小鼠随机分为4组,分别腹腔注射LPS 5 mg·kg - 1、2.5 mg·kg - 1和1.25 mg·kg - 1和生理盐水。结果:腹腔注射LPS 5 mg·kg - 1、2.5 mg·kg - 1组动物肾脏病理改变符合SLE病理特点,动物24小时尿蛋白含量、血清ANA的滴度、肾脏免疫复合物光密度均明显升高,而腹腔注射LPS 5 mg·kg - 1组动物死亡率明显升高。结果:腹腔注射LPS 5 mg·kg- 1、2.5 mg·kg - 1均能制造出良好的狼疮性肾炎模型,而腹腔注射LPS 5 mg·kg- 1动物死亡率高。
第二步分中西医结合治疗对SLE模型鼠疗效观察
目的:探讨中西医结合治疗对SLE模型鼠的疗效。方法:120只小鼠腹腔注射2.5 mg·kg - 1制造SLE模型鼠,随机分为6组,分别给予蒸馏水、中药清热解毒补肾方、强的松、环磷酰胺、清热解毒补肾方+强的松、清热解毒补肾方+环磷酰胺在造模的同时灌胃治疗15天。结果:与对照组相比,各治疗组动物死亡率、24小时尿蛋白含量、血清ANA的滴度、肾小球免疫复合物沉积均有不同程度的下降,以中西医结合治疗组降低最为明显。结论:中药清热解毒补肾方及西药强的松、环磷酰胺对狼疮样小鼠模型均有良好的治疗作用,而中西医结合治疗效果最好。
Part One Induction of lupus nephritis models of intraperitoneal injection lipopolysaccharide
Objective:To investigate the method to establish murine lupus nephritis models by intraperitoneal injection lipopolysaccharide (LPS). Methods: 80 mice were divided into four groups and were given NS or three different LPS doses (5mg*kg-1, 2.5mg*kg-1, 1.25mg*kg-1) respectively. Results: Compared with control group, the pathological change of kidney were appeared in 5mg*kg-1 and 2.5mg*kg-1 groups. The content of protein in 24 hours urine, the serum antinuclear antibody, and the deposition status of immune complex in nephritis of lupus were remarkably increased in 5mg*kg-1 group and 2.5mg*kg-1 groups than those in control group and 1.25mg*kg-1 group. The mortality of mice with LPS i.p in 5mg*kg-1 group was remarkably increased than that in other groups. Conclusion: The dose of LPS with 2.5mg*kg-1 i.p. injected can induce lower mortality than with 5mg*kg-1 in establishing SLE models and it can be used as an appropriate model for further research.
Part Two Effects of combined treatment of traditional Chinese medicine and western medicine on Murine Lupus Nephritis Models
Objective: To study the effects of combined treatment of traditional Chinese medicine and western medicine on Murine Lupus Nephritis Models. Methods:120 mice were made to murine lupus nephritis models with LPS by intraperitoneal injection. These mice were divided into six groups and were given distilled water, Qingrejiedubushen Decoction, prednisone, cyclophosphamide, Bushenqingrejiedu Decoction plus prednisone, and Qingrejiedubushen Decoction plus cyclophosphamide by intragastric administration (1 time per day) for 15 days respectively. Results: Compared with control group, the mortality, the content of protein in 24 hours urine, the serum antinuclear antibody, and the deposition status of immune complex in nephritis of lupus were remarkably decreased in all treatment groups, especially in combined treatment of traditional Chinese medicine and western medicine groups. Conclusion : Prednisone, cyclophosphamide, and Qingrejiedubushen Decoction all have therapeutic effects on Murine Lupus Nephritis Models, and the therapeutic effects of combination of traditional Chinese medicine and western medicine are better than others.
目的:探讨腹腔注射细菌脂多糖(LPS)制造SLE小鼠模型的最佳剂量。方法:80只小鼠随机分为4组,分别腹腔注射LPS 5 mg·kg - 1、2.5 mg·kg - 1和1.25 mg·kg - 1和生理盐水。结果:腹腔注射LPS 5 mg·kg - 1、2.5 mg·kg - 1组动物肾脏病理改变符合SLE病理特点,动物24小时尿蛋白含量、血清ANA的滴度、肾脏免疫复合物光密度均明显升高,而腹腔注射LPS 5 mg·kg - 1组动物死亡率明显升高。结果:腹腔注射LPS 5 mg·kg- 1、2.5 mg·kg - 1均能制造出良好的狼疮性肾炎模型,而腹腔注射LPS 5 mg·kg- 1动物死亡率高。
第二步分中西医结合治疗对SLE模型鼠疗效观察
目的:探讨中西医结合治疗对SLE模型鼠的疗效。方法:120只小鼠腹腔注射2.5 mg·kg - 1制造SLE模型鼠,随机分为6组,分别给予蒸馏水、中药清热解毒补肾方、强的松、环磷酰胺、清热解毒补肾方+强的松、清热解毒补肾方+环磷酰胺在造模的同时灌胃治疗15天。结果:与对照组相比,各治疗组动物死亡率、24小时尿蛋白含量、血清ANA的滴度、肾小球免疫复合物沉积均有不同程度的下降,以中西医结合治疗组降低最为明显。结论:中药清热解毒补肾方及西药强的松、环磷酰胺对狼疮样小鼠模型均有良好的治疗作用,而中西医结合治疗效果最好。
Part One Induction of lupus nephritis models of intraperitoneal injection lipopolysaccharide
Objective:To investigate the method to establish murine lupus nephritis models by intraperitoneal injection lipopolysaccharide (LPS). Methods: 80 mice were divided into four groups and were given NS or three different LPS doses (5mg*kg-1, 2.5mg*kg-1, 1.25mg*kg-1) respectively. Results: Compared with control group, the pathological change of kidney were appeared in 5mg*kg-1 and 2.5mg*kg-1 groups. The content of protein in 24 hours urine, the serum antinuclear antibody, and the deposition status of immune complex in nephritis of lupus were remarkably increased in 5mg*kg-1 group and 2.5mg*kg-1 groups than those in control group and 1.25mg*kg-1 group. The mortality of mice with LPS i.p in 5mg*kg-1 group was remarkably increased than that in other groups. Conclusion: The dose of LPS with 2.5mg*kg-1 i.p. injected can induce lower mortality than with 5mg*kg-1 in establishing SLE models and it can be used as an appropriate model for further research.
Part Two Effects of combined treatment of traditional Chinese medicine and western medicine on Murine Lupus Nephritis Models
Objective: To study the effects of combined treatment of traditional Chinese medicine and western medicine on Murine Lupus Nephritis Models. Methods:120 mice were made to murine lupus nephritis models with LPS by intraperitoneal injection. These mice were divided into six groups and were given distilled water, Qingrejiedubushen Decoction, prednisone, cyclophosphamide, Bushenqingrejiedu Decoction plus prednisone, and Qingrejiedubushen Decoction plus cyclophosphamide by intragastric administration (1 time per day) for 15 days respectively. Results: Compared with control group, the mortality, the content of protein in 24 hours urine, the serum antinuclear antibody, and the deposition status of immune complex in nephritis of lupus were remarkably decreased in all treatment groups, especially in combined treatment of traditional Chinese medicine and western medicine groups. Conclusion : Prednisone, cyclophosphamide, and Qingrejiedubushen Decoction all have therapeutic effects on Murine Lupus Nephritis Models, and the therapeutic effects of combination of traditional Chinese medicine and western medicine are better than others.
引文
[1] 王海燕,主编.肾脏病学,北京:人民卫生出版社,1996,第二版:861-865.
[2] 杨国亮,王侠生,主编.现代皮肤病学,上海:上海医科大学出版社,1996,第一版:540-550.
[3] 黄咏菁.系统性红斑狼疮中西医研究进展.陕西中医,2003;24(12):1139-1142.
[4] 李博,叶志中,庄俊汉.系统性红斑狼疮治疗研究进展.中华风湿病学杂志,2004;8(1):46-50.
[5] 赵会芳,钟嘉熙,彭胜权,等.青蒿素复方对 SLE 模型小鼠作用的研究.中国中医药信息杂志,1998;5(8):18-19.
[6] 高蓉,谢艳华,王四旺,等.SLE 小鼠血清中自身抗体检测.第四军医大学学报,2003;24(10):887-889.
[7] 李兆福,彭江云.系统性红斑狼疮的中医药研究进展.云南中医中药杂志,2005;25(5):33-36.
[8] 盛 梅 笑 , 金 实 . 中 医 治 疗 狼 疮 性 肾 炎 研 究 进 展 . 中 国 中 医 药 信 息 杂志,2003;10(6):90-92.
[9] 吴晓霞,禤国维,陈达灿.系统性红斑狼疮的中医药研究进展.中国中医药信息杂志,2004;11(1):84-86.
[10] Andrews BS, Eisenberg RA, Theofilopoulos AN, et al. Spontaneous murine lupus-like syndromes.Clinical and immunopathological manifestations in several strains. J Exp Med,1978; 148:1198-1215.
[11] Boswell JM, Yui MA, Endres S, et al. Novel and enhanced IL-1 gene expression in autoimmune mice with lupus.J Immunol, 1988;141:118-124.
[12] Tang B, Matsuda T, Akira N, et al. Age-associated increase in interleukin 6 in MRL/lpr mice. Int Immunol, 1991; 3:273-278.
[13] yui MA, Brissette WH, Brennan DC, et al. Increased macrophage colony-stimulating factor in neonatal and adult autoimmune MRL-lpr mice.Am J pathol, 1991; 139:255-261.
[14] Hirose S, Jiang Y, Hamano Y, et al. Genetic aspects of inherent B-cellabnormalities associated with SLE and B-cell malignancy:lessons from New Zealand moude models.Intern Rev Immunol, 2000; 19:389-421.
[15] Murphy ED, Roths JB. A Y chromosome-associated factor in strain BXSB producing accelerated autoimmunity and lymphoproliferation. Arthritis Rheum, 1979;22(11):1188-1194.
[16] 杨高云,袁勇,姜学义,等.IL-10基因给药对BXSB狼疮小鼠发病的影响.中国皮肤性病学杂志,1998;12(4):197-199.
[17] Theofilqpoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol, 1985; 37:269.
[18] 徐 志 伟 , 李 文 静 .Yaa 基 因 与 狼 疮 性 BXSB 小 鼠 . 国 外 医 学 . 免 疫 学 分册,2000;23(2):86-83.
[19] 徐志伟,邓鸿业.BXSB小鼠胸腺内B细胞异常增生机理的初步分析.潍坊医学院学报,1996;18(3):191-192.
[20] 周素荣,刘传玉,徐世正,等.SLE 的 BXSB 小鼠模型病情进展状况的研究.中国麻风皮肤病杂志,2002;18(2):112-114.
[21] 周素荣,徐世正,刘传玉,等.红斑狼疮样雄性 BXSB 小鼠模型肾脏受累状况的研究. 武汉大学学报(医学版),2003;24(4):347-349.
[22] 梅林,汪静雪,邓鸿业,等.BXSB 小鼠血清抗 DNA 抗体水平及其对淋巴细胞转化的影响.基础医学与临床,2000;20(1):34-37.
[23] 徐志伟,邓鸿业,邓玉兰,等.狼疮性BXSB小鼠抗DNA抗体水平的动态变化.免疫学杂志,2000;16(1):13-15.
[24] 邓鸿业,邓玉兰,王桂琴,等.BXSB 小鼠的免疫学及免疫病理学研究.中国免疫学杂志,1991;7:127-128.
[25] 林晨,谢雅莉,沈莉等。同种异体淋巴细胞诱导的 SLE 样小鼠模型。上海免疫学杂志,1989;9(2):73.
[26] Shlomo Mendlovic, Stefan Brocke, Yehuda Shoenfeld, et al. Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype. Proc Natl Acad Sci USA, 1988;85:2260.
[27] Appleby P, Webber DG, Bowen JG. Murine chronic graft-versus-host diseaseas a model of systemic lupus erythematosus: effect of immunosuppressive drugs on disease development. Clin Exp Immunl, 1989; 78:449.
[28] 周玲玲,魏伟,徐叔云.系统性红斑狼疮动物模型及药物作用研究.安徽医科大学学报,2000;35(5):359.
[29] Tito Cavallo, et al. Proliferative glomerulonephritis associated with polyclonal B-cell activation Animal model of human disease.American J Patho, l 984;114:346.
[30] Francisco, et a1. Induction of circulation immune complexes and their renal localization after acute or chronic polyclonal B-cell activation in mice. Kidney International, 1982;2:29.
[31] Izui S, Lambert PH, Fournie GJ, Turler H, et al. Features of systemic lupus erythematosus in mice injected with bacterial lopolysaccharides: identificantion of circulating DNA and renal localization of DNA-anti-DNA complexes.J Exp Med, 1977; 145(5):1115-1130.
[32] Strasser A, Whittingham S, Vaux DL, et al. Enforecd Bcl-2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA, 1991;88: 8661-8665.
[33] Utz PJ, Hottelet M, Schur PH,et al.Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med, 1997; 185(5):843-854.
[34] Tax WJ, Kramers C, van Bruggen MC,et al. Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus. Kidney Int,1995; 48(3):666-673.
[35] Van Bruggen MC, Kramers C, et al. Autoimmunity against nucleosomes and lupus nephritis.Ann Med Interne,1996; 147(7):485-489.
[36] Suzuki N, Mihara S, Sakane T. Development of pathogenic anti-DNA antibodies in patients with systemic lupus erythematosus. J FASEB, 1997; 11(12):1033-1038.
[37] Suzuki N, Harada T, Mihara S,et al. Characterization of a germline Vk gene encoding cationic anti-DNA antibody and role of receptor editing for development of the autoantibody in patients with systemic lupus erythematosus. J Clin Invest, 1996; 98(8):1843-50.
[38] Kramers C, Hylkema MN, van Bruggen MC,et al. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest, 1994; 94(2):568-77
[39] Vyse TJ, Drake CG, Rozzo SJ,et al. Genetic linkage of IgG autoantibody production in relation to lupus nephritis in New Zealand hybrid mice.J Clin Invest, 1996; 98(8):1762-72
[40] 李壁霞. 自身免疫性疾病的遗传因素和基因治疗. 国外医学免疫学分册, 2000; 23(6):328-331.
[41] 尹培达,陈永雄,王丹,等.狼疮性肾炎发病机理和临床研究.中山医科大学学报, 1998;19(2):81-85.
[42] 王 红 艳 . 自 身 免 疫 疾 病 中 Th1/Th2 细 胞 平 衡 . 国 外 医 学 免 疫 学 分册,2000;23(6):348-350.
[43] 周道远.系统性红斑狼疮中的免疫细胞信号传导异常.国外医学免疫学分册,2000;23(5):284-286.
[44] 赵同峰,刘章锁,张明轩.细胞凋亡与系统性红斑狼疮.中华肾脏病杂志,1999;15(2):124-125.
[45] 汉·张机.金匾要略方论.卷上,北京:人民卫生出版社影印,1982:15.
[46] 隋·巢元方.诸病源候论.卷八,北京:人民卫生出版社,1982,第一版:48.
[47] 隋·巢元方.诸病源候论.卷八,北京:人民卫生出版社,1982, 第一版:62.
[48] 叶天士·临证指南医案,上海:上海人民出版社,1957,第一版:538.
[49] 叶天士·临证指南医案,上海:上海人民出版社,1957,第一版:157.
[50] Gourley MF, Austin HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med, 1996; 125:549.
[51] De Pita O, Bellucct AM, Ruffelli M, et al. Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestanons in patients with lupus erythematosus. Lupus, 1997; 6:415.
[52] Levy Y, Sherer Y, Ahmed A, et al. A study of 29 SLE patients with intravenous immunogloblin: clinical and serologic reponse. Lupus. 1999; 8:705.
[53] Boletis J, Ioannidis JPA, Boki KA, et al. Intravenous immunoglobulin compared with cyclophosphamide for proliferatibe lupus nephritis. Lancet, 1999;354:569.
[54] Caccavo D, Lagana B, Mitterhofer AP, et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum,1997; 40:27.
[55] Baca, V, Catalan, T, Villasis-Keever, M, et al. Effect of low-dose cyclosporine A in the treatment of refractory proteinuria in childhood-onset lupus nephritis. Lupus. 2006; 15(8): 490–495.
[56] Stevens RJ, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol, 1997; 36:353.
[57] Petri M. Mycophenolate mofetil treatment of systemic lupus erythematosus (abstract). Arthritis Rheum, 1999; 42:S303.
[58] Han TM, Li FK, Tang CSO,et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med, 2000;343:1156.
[59] 杜晓棠,林琳,叶任高.干细胞移植治疗 SLE 的研究进展.中国中西医结合肾病杂志,2003;4(10):612-614.
[60] 王萍,张芃,张志礼.张志礼治疗系统性红斑狼疮经验.北京中医,1999;(2):5-6.
[61] 曹慧芬,林丽,孟如.孟如教授治疗红斑狼疮的经验.云南中医中药杂志,1999;20(5):1-3.
[62] 顾美华,陈志伟,邓迎苏.中西医结合治疗系统性红斑狼疮 54 例临床观察.江苏中医药,2002;23(4):22-23.
[63] 袁兆庄,冯景春.复方秦艽片加少量激素治疗红斑狼疮的疗效观察.中西医结合杂志,1989;9(3):156-157.
[64] 丁丛礼,丁嬴,刘发,等.抗狼疮散治疗系统性红斑狼疮的临床及实验研究.中药药理与临床,1995;11(4):45-49.
[65] 钟 嘉 熙 , 刘 亚 敏 , 张 剑 勇 . 苓 丹 片 治 疗 系 统 性 红 斑 狼 疮 149 例 . 新 中医,1997;29(11):12-14.
[66] 明·李时珍.本草纲目,北京:人民卫生出版社,1982,第一版:228.
[67] 娄红祥,郎伟君,吕木坚.金银花中水溶性化合物的分离与结构确定.中草药,1996;27(4):195.
[68] 巫朝伦,刘珊,马福家,等.白花蛇舌草的化学成分、药理作用和临床应用.沈阳部队医药.2003;16(5):436-437.
[69] 崔健,施松善,王顺春,等.白花蛇舌草的化学成分及药理作用研究进展.上海中医药杂志.2005;39(7):57-59.
[70] 马超,朴惠善.白花蛇舌草的研究进展.时珍国医国药.2006;17(2):269-270.
[71] 王兆全,王先荣,扬志华.红藤化学成分的研究.中草药,1982;12(3):7-9.
[72] 蒋洪,刘乐乐.中药红藤化学成份及临床作用的研究进展.内蒙古科技与经济, 2002;3:120,127.
[73] 武晓敏,朱美莲,应小飞.复方红藤汤的研制及临床应用.中成药.2003;25(5):附1-附 2.
[74] 中华本草编委会.中华本草,上海:上海科技出版社,1998,第一版:338.
[75] 王霞,凌世峰.虎杖药理作用研究进展.海军医学杂志,2004;25(2):179-181.
[76] 裴莲花,吴学,金光洙.虎杖化学成分及药理作用研究现状.延边大学医学学报,2006;29(2):147-149.
[77] 芦丽,李建青.虎杖药理作用研究进展.临沂医学专科学校学报,2002;25(1): 46-47.
[78] 朱燕飞.枸杞的药理作用概述.浙江中西医结合杂志,2005;15(5):322-323.
[79] 刘秀英,孙世成,王英淑,等.枸杞子的临床应用.邯郸医学高等专科学校学报,2004;17(6):518-519.
[80] 王振中.五味子的药理研究进展.时珍国药研究,1996;7(2):119-121.
[81] 倪立东,陈延西.五味子药理作用研究概况(综述).暨南大学学报(医学版),1996;17(2):125-128.
[82] 张晶,陆定奕.中药五味子化学成份和药理作用研究及临床应用.上海预防医学杂志,1997;9(4):189-190.
[83] 刘 继 永 , 王 英 平 , 刘 洪 章 . 五 味 子 化 学 成 分 及 药 理 研 究 进 展 . 特 产 研究,2005;(3):49-53.
[84] 郭冷秋,张鹏,黄莉莉.五味子药理作用研究进展.中医药学报,2006;34(4):51-53.
[85] 王雅贤,王丽,王惠国等.祛毒胶囊对狼疮样小鼠外周血白细胞介素-6、干扰素-γ和肿瘤坏死因子-α的影响.牡丹江医学院学报,2004;25(6):5-7.
[86] Cheng WF. Medical immunology, Beijing: Beijing Renming Weishen Chubanshe ( Peopleps Medical Publishing House) , 2000, 3rd:210 - 211.
[87] 董德长.实用肾脏病学,上海:上海科学出版社,1999,第一版:991-998.
[88] 沈庆法,扬进,宋乃光.温病学说之研究,上海:上海中医药大学出版社,2000,第一版:134-136.
[89] 王发国,叶华谷,马其侠,等.金银花及其药理作用.生物学通报,2004; 39(5):17-18
[2] 杨国亮,王侠生,主编.现代皮肤病学,上海:上海医科大学出版社,1996,第一版:540-550.
[3] 黄咏菁.系统性红斑狼疮中西医研究进展.陕西中医,2003;24(12):1139-1142.
[4] 李博,叶志中,庄俊汉.系统性红斑狼疮治疗研究进展.中华风湿病学杂志,2004;8(1):46-50.
[5] 赵会芳,钟嘉熙,彭胜权,等.青蒿素复方对 SLE 模型小鼠作用的研究.中国中医药信息杂志,1998;5(8):18-19.
[6] 高蓉,谢艳华,王四旺,等.SLE 小鼠血清中自身抗体检测.第四军医大学学报,2003;24(10):887-889.
[7] 李兆福,彭江云.系统性红斑狼疮的中医药研究进展.云南中医中药杂志,2005;25(5):33-36.
[8] 盛 梅 笑 , 金 实 . 中 医 治 疗 狼 疮 性 肾 炎 研 究 进 展 . 中 国 中 医 药 信 息 杂志,2003;10(6):90-92.
[9] 吴晓霞,禤国维,陈达灿.系统性红斑狼疮的中医药研究进展.中国中医药信息杂志,2004;11(1):84-86.
[10] Andrews BS, Eisenberg RA, Theofilopoulos AN, et al. Spontaneous murine lupus-like syndromes.Clinical and immunopathological manifestations in several strains. J Exp Med,1978; 148:1198-1215.
[11] Boswell JM, Yui MA, Endres S, et al. Novel and enhanced IL-1 gene expression in autoimmune mice with lupus.J Immunol, 1988;141:118-124.
[12] Tang B, Matsuda T, Akira N, et al. Age-associated increase in interleukin 6 in MRL/lpr mice. Int Immunol, 1991; 3:273-278.
[13] yui MA, Brissette WH, Brennan DC, et al. Increased macrophage colony-stimulating factor in neonatal and adult autoimmune MRL-lpr mice.Am J pathol, 1991; 139:255-261.
[14] Hirose S, Jiang Y, Hamano Y, et al. Genetic aspects of inherent B-cellabnormalities associated with SLE and B-cell malignancy:lessons from New Zealand moude models.Intern Rev Immunol, 2000; 19:389-421.
[15] Murphy ED, Roths JB. A Y chromosome-associated factor in strain BXSB producing accelerated autoimmunity and lymphoproliferation. Arthritis Rheum, 1979;22(11):1188-1194.
[16] 杨高云,袁勇,姜学义,等.IL-10基因给药对BXSB狼疮小鼠发病的影响.中国皮肤性病学杂志,1998;12(4):197-199.
[17] Theofilqpoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol, 1985; 37:269.
[18] 徐 志 伟 , 李 文 静 .Yaa 基 因 与 狼 疮 性 BXSB 小 鼠 . 国 外 医 学 . 免 疫 学 分册,2000;23(2):86-83.
[19] 徐志伟,邓鸿业.BXSB小鼠胸腺内B细胞异常增生机理的初步分析.潍坊医学院学报,1996;18(3):191-192.
[20] 周素荣,刘传玉,徐世正,等.SLE 的 BXSB 小鼠模型病情进展状况的研究.中国麻风皮肤病杂志,2002;18(2):112-114.
[21] 周素荣,徐世正,刘传玉,等.红斑狼疮样雄性 BXSB 小鼠模型肾脏受累状况的研究. 武汉大学学报(医学版),2003;24(4):347-349.
[22] 梅林,汪静雪,邓鸿业,等.BXSB 小鼠血清抗 DNA 抗体水平及其对淋巴细胞转化的影响.基础医学与临床,2000;20(1):34-37.
[23] 徐志伟,邓鸿业,邓玉兰,等.狼疮性BXSB小鼠抗DNA抗体水平的动态变化.免疫学杂志,2000;16(1):13-15.
[24] 邓鸿业,邓玉兰,王桂琴,等.BXSB 小鼠的免疫学及免疫病理学研究.中国免疫学杂志,1991;7:127-128.
[25] 林晨,谢雅莉,沈莉等。同种异体淋巴细胞诱导的 SLE 样小鼠模型。上海免疫学杂志,1989;9(2):73.
[26] Shlomo Mendlovic, Stefan Brocke, Yehuda Shoenfeld, et al. Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype. Proc Natl Acad Sci USA, 1988;85:2260.
[27] Appleby P, Webber DG, Bowen JG. Murine chronic graft-versus-host diseaseas a model of systemic lupus erythematosus: effect of immunosuppressive drugs on disease development. Clin Exp Immunl, 1989; 78:449.
[28] 周玲玲,魏伟,徐叔云.系统性红斑狼疮动物模型及药物作用研究.安徽医科大学学报,2000;35(5):359.
[29] Tito Cavallo, et al. Proliferative glomerulonephritis associated with polyclonal B-cell activation Animal model of human disease.American J Patho, l 984;114:346.
[30] Francisco, et a1. Induction of circulation immune complexes and their renal localization after acute or chronic polyclonal B-cell activation in mice. Kidney International, 1982;2:29.
[31] Izui S, Lambert PH, Fournie GJ, Turler H, et al. Features of systemic lupus erythematosus in mice injected with bacterial lopolysaccharides: identificantion of circulating DNA and renal localization of DNA-anti-DNA complexes.J Exp Med, 1977; 145(5):1115-1130.
[32] Strasser A, Whittingham S, Vaux DL, et al. Enforecd Bcl-2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA, 1991;88: 8661-8665.
[33] Utz PJ, Hottelet M, Schur PH,et al.Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med, 1997; 185(5):843-854.
[34] Tax WJ, Kramers C, van Bruggen MC,et al. Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus. Kidney Int,1995; 48(3):666-673.
[35] Van Bruggen MC, Kramers C, et al. Autoimmunity against nucleosomes and lupus nephritis.Ann Med Interne,1996; 147(7):485-489.
[36] Suzuki N, Mihara S, Sakane T. Development of pathogenic anti-DNA antibodies in patients with systemic lupus erythematosus. J FASEB, 1997; 11(12):1033-1038.
[37] Suzuki N, Harada T, Mihara S,et al. Characterization of a germline Vk gene encoding cationic anti-DNA antibody and role of receptor editing for development of the autoantibody in patients with systemic lupus erythematosus. J Clin Invest, 1996; 98(8):1843-50.
[38] Kramers C, Hylkema MN, van Bruggen MC,et al. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest, 1994; 94(2):568-77
[39] Vyse TJ, Drake CG, Rozzo SJ,et al. Genetic linkage of IgG autoantibody production in relation to lupus nephritis in New Zealand hybrid mice.J Clin Invest, 1996; 98(8):1762-72
[40] 李壁霞. 自身免疫性疾病的遗传因素和基因治疗. 国外医学免疫学分册, 2000; 23(6):328-331.
[41] 尹培达,陈永雄,王丹,等.狼疮性肾炎发病机理和临床研究.中山医科大学学报, 1998;19(2):81-85.
[42] 王 红 艳 . 自 身 免 疫 疾 病 中 Th1/Th2 细 胞 平 衡 . 国 外 医 学 免 疫 学 分册,2000;23(6):348-350.
[43] 周道远.系统性红斑狼疮中的免疫细胞信号传导异常.国外医学免疫学分册,2000;23(5):284-286.
[44] 赵同峰,刘章锁,张明轩.细胞凋亡与系统性红斑狼疮.中华肾脏病杂志,1999;15(2):124-125.
[45] 汉·张机.金匾要略方论.卷上,北京:人民卫生出版社影印,1982:15.
[46] 隋·巢元方.诸病源候论.卷八,北京:人民卫生出版社,1982,第一版:48.
[47] 隋·巢元方.诸病源候论.卷八,北京:人民卫生出版社,1982, 第一版:62.
[48] 叶天士·临证指南医案,上海:上海人民出版社,1957,第一版:538.
[49] 叶天士·临证指南医案,上海:上海人民出版社,1957,第一版:157.
[50] Gourley MF, Austin HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med, 1996; 125:549.
[51] De Pita O, Bellucct AM, Ruffelli M, et al. Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestanons in patients with lupus erythematosus. Lupus, 1997; 6:415.
[52] Levy Y, Sherer Y, Ahmed A, et al. A study of 29 SLE patients with intravenous immunogloblin: clinical and serologic reponse. Lupus. 1999; 8:705.
[53] Boletis J, Ioannidis JPA, Boki KA, et al. Intravenous immunoglobulin compared with cyclophosphamide for proliferatibe lupus nephritis. Lancet, 1999;354:569.
[54] Caccavo D, Lagana B, Mitterhofer AP, et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum,1997; 40:27.
[55] Baca, V, Catalan, T, Villasis-Keever, M, et al. Effect of low-dose cyclosporine A in the treatment of refractory proteinuria in childhood-onset lupus nephritis. Lupus. 2006; 15(8): 490–495.
[56] Stevens RJ, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol, 1997; 36:353.
[57] Petri M. Mycophenolate mofetil treatment of systemic lupus erythematosus (abstract). Arthritis Rheum, 1999; 42:S303.
[58] Han TM, Li FK, Tang CSO,et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med, 2000;343:1156.
[59] 杜晓棠,林琳,叶任高.干细胞移植治疗 SLE 的研究进展.中国中西医结合肾病杂志,2003;4(10):612-614.
[60] 王萍,张芃,张志礼.张志礼治疗系统性红斑狼疮经验.北京中医,1999;(2):5-6.
[61] 曹慧芬,林丽,孟如.孟如教授治疗红斑狼疮的经验.云南中医中药杂志,1999;20(5):1-3.
[62] 顾美华,陈志伟,邓迎苏.中西医结合治疗系统性红斑狼疮 54 例临床观察.江苏中医药,2002;23(4):22-23.
[63] 袁兆庄,冯景春.复方秦艽片加少量激素治疗红斑狼疮的疗效观察.中西医结合杂志,1989;9(3):156-157.
[64] 丁丛礼,丁嬴,刘发,等.抗狼疮散治疗系统性红斑狼疮的临床及实验研究.中药药理与临床,1995;11(4):45-49.
[65] 钟 嘉 熙 , 刘 亚 敏 , 张 剑 勇 . 苓 丹 片 治 疗 系 统 性 红 斑 狼 疮 149 例 . 新 中医,1997;29(11):12-14.
[66] 明·李时珍.本草纲目,北京:人民卫生出版社,1982,第一版:228.
[67] 娄红祥,郎伟君,吕木坚.金银花中水溶性化合物的分离与结构确定.中草药,1996;27(4):195.
[68] 巫朝伦,刘珊,马福家,等.白花蛇舌草的化学成分、药理作用和临床应用.沈阳部队医药.2003;16(5):436-437.
[69] 崔健,施松善,王顺春,等.白花蛇舌草的化学成分及药理作用研究进展.上海中医药杂志.2005;39(7):57-59.
[70] 马超,朴惠善.白花蛇舌草的研究进展.时珍国医国药.2006;17(2):269-270.
[71] 王兆全,王先荣,扬志华.红藤化学成分的研究.中草药,1982;12(3):7-9.
[72] 蒋洪,刘乐乐.中药红藤化学成份及临床作用的研究进展.内蒙古科技与经济, 2002;3:120,127.
[73] 武晓敏,朱美莲,应小飞.复方红藤汤的研制及临床应用.中成药.2003;25(5):附1-附 2.
[74] 中华本草编委会.中华本草,上海:上海科技出版社,1998,第一版:338.
[75] 王霞,凌世峰.虎杖药理作用研究进展.海军医学杂志,2004;25(2):179-181.
[76] 裴莲花,吴学,金光洙.虎杖化学成分及药理作用研究现状.延边大学医学学报,2006;29(2):147-149.
[77] 芦丽,李建青.虎杖药理作用研究进展.临沂医学专科学校学报,2002;25(1): 46-47.
[78] 朱燕飞.枸杞的药理作用概述.浙江中西医结合杂志,2005;15(5):322-323.
[79] 刘秀英,孙世成,王英淑,等.枸杞子的临床应用.邯郸医学高等专科学校学报,2004;17(6):518-519.
[80] 王振中.五味子的药理研究进展.时珍国药研究,1996;7(2):119-121.
[81] 倪立东,陈延西.五味子药理作用研究概况(综述).暨南大学学报(医学版),1996;17(2):125-128.
[82] 张晶,陆定奕.中药五味子化学成份和药理作用研究及临床应用.上海预防医学杂志,1997;9(4):189-190.
[83] 刘 继 永 , 王 英 平 , 刘 洪 章 . 五 味 子 化 学 成 分 及 药 理 研 究 进 展 . 特 产 研究,2005;(3):49-53.
[84] 郭冷秋,张鹏,黄莉莉.五味子药理作用研究进展.中医药学报,2006;34(4):51-53.
[85] 王雅贤,王丽,王惠国等.祛毒胶囊对狼疮样小鼠外周血白细胞介素-6、干扰素-γ和肿瘤坏死因子-α的影响.牡丹江医学院学报,2004;25(6):5-7.
[86] Cheng WF. Medical immunology, Beijing: Beijing Renming Weishen Chubanshe ( Peopleps Medical Publishing House) , 2000, 3rd:210 - 211.
[87] 董德长.实用肾脏病学,上海:上海科学出版社,1999,第一版:991-998.
[88] 沈庆法,扬进,宋乃光.温病学说之研究,上海:上海中医药大学出版社,2000,第一版:134-136.
[89] 王发国,叶华谷,马其侠,等.金银花及其药理作用.生物学通报,2004; 39(5):17-18